Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas

OBJECTIVE: This study sought to determine whether pretreatment pan-immune-inflammation value (PIV) could be used to predict prognosis in patients with locally advanced pancreatic adenocarcinoma (LA-PAC) following definitive concurrent chemoradiotherapy (C-CRT). METHODS: The outcomes of 178 LA-PAC pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Topkan, Erkan, Selek, Ugur, Kucuk, Ahmet, Pehlivan, Berrin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499729/
https://www.ncbi.nlm.nih.gov/pubmed/36158517
http://dx.doi.org/10.2147/JIR.S385328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499729/
https://www.ncbi.nlm.nih.gov/pubmed/36158517
http://dx.doi.org/10.2147/JIR.S385328

Ejemplares similares